Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. provides long-term care pharmacy services for residents of long-term health care facilities. The company partners with LTCFs through a locally based pharmacy model to dispense medications and deliver technology-enabled clinical and administration services intended to support drug-regimen adherence and reduce medication-administration errors.
Recurring GRDN news covers quarterly results and guidance, resident and prescription-volume trends, the effects of drug-pricing changes, healthcare conference presentations, and capital-structure activity involving Class A common stock. Company updates also reference its pharmacy network, facility relationships, and service categories across assisted living, behavioral health, group home, and other long-term care settings.
Guardian Pharmacy Services (NYSE: GRDN) announced the acquisition of assets from Tennessee-based Nautilus Pharmacy, including prescription files, related pharmacy inventory, and certain fixed assets. Nautilus serves assisted living communities across 14 states, primarily via mail order from a single centralized pharmacy.
Guardian will transition Nautilus-served residents to 18 Guardian pharmacies in the markets where they reside, shifting services from centralized mail order to locally managed long-term care pharmacies. According to the company, this gives former Nautilus community partners access to Guardian’s broader LTC pharmacy capabilities, technology, and national resources while retaining local service.
The integration is being led by senior vice president David Brown, in collaboration with regional leaders and local pharmacy teams. Guardian plans to hire more than half of Nautilus employees, including pharmacists and technicians, and describes the transaction as aligned with its disciplined growth strategy and an efficient use of capital by leveraging existing pharmacy capacity.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026, in a fireside chat featuring President and CEO Fred Burke at 2:25 p.m. CST. A live audio webcast will be available to investors, analysts, media, and the public via the company’s investor relations website.
Guardian Pharmacy Services (NYSE: GRDN) reported second-quarter 2026 revenue of $351.8 million, up 2% year-over-year, serving approximately 210,000 residents, up 8%. Net income was $22.1 million, including an $8.5 million payor-dispute settlement, versus $8.8 million a year ago, and Adjusted EBITDA reached $29.7 million compared with $25.0 million. Diluted EPS was $0.34 and Adjusted EPS $0.29. Cash and equivalents totaled $89.8 million with no long-term debt under the credit facility.
Based on year-to-date performance, Guardian raised full-year 2026 guidance to $1.43–$1.45 billion in revenue and $129–$131 million in Adjusted EBITDA. Post quarter-end, it acquired Wellness Concepts in Virginia and opened a greenfield pharmacy in Lexington, Kentucky, while also implementing leadership changes including a new COO and CFO and a regional structure led by eight senior vice presidents.
Guardian Pharmacy Services (NYSE: GRDN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will discuss the results on a conference call at 4:30 p.m. Eastern Time, accessible via audio webcast and dedicated phone lines for U.S., Canada, and international participants.
A webcast replay will be available shortly after the call’s completion through the company’s investor relations website.
Guardian Pharmacy Services (NYSE: GRDN) announced the acquisition of Wellness Concepts, an LTC pharmacy in Grottoes, Virginia. This expands Guardian’s Virginia footprint to three pharmacies in Gainesville, Wytheville, and Grottoes.
Wellness Concepts keeps its leadership and staff, while gaining Guardian’s national clinical, operational, and technology support.
Guardian Pharmacy Services (NYSE: GRDN) announced leadership transitions effective July 1, 2026. Long-time Executive Vice President of Sales & Operations Kendall Forbes will retire. David Morris, currently EVP and CFO, becomes Chief Operating Officer, and Will Mudd, Senior Vice President, Finance, is appointed Chief Financial Officer.
Guardian highlights internal succession, leadership depth, and its focus on developing talent from within as it continues to grow.
Guardian Pharmacy Services (NYSE: GRDN) reported Q1 2026 results: revenue $336.6M (+2% YoY), net income $13.5M, adjusted EBITDA $29.8M, and diluted EPS $0.21. Cash was $64.9M with no long-term debt under the credit facility. Residents served rose to ~207,000 (+10% YoY). Updated FY2026 guidance: revenue $1.40B–$1.42B, adjusted EBITDA $123M–$127M. Company completed a non-dilutive secondary offering increasing public float and filed a new shelf registration; no proceeds retained and no change to outstanding Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Bank of America 2026 Healthcare Conference in Las Vegas on Wednesday, May 13, 2026. Fred Burke, President and CEO, will take part in a 9:20 a.m. PDT fireside chat. A live audio webcast will be available via the company's investor website.
Guardian Pharmacy Services (NYSE: GRDN) will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Management will host a conference call at 4:30 p.m. ET to discuss results.
The call will stream via audio webcast at the company's investor site and is reachable by U.S./Canada dial-in +1 (833) 461-5787, international +1 (585) 542-9983, conference ID 621845633. A replay will be available shortly after the call.
Guardian Pharmacy Services (NYSE: GRDN) priced an upsized underwritten public offering of 6,000,000 Class A shares at $31.00 per share, expected to close on March 20, 2026. 4,980,000 shares are being sold by selling stockholders and 1,020,000 shares are a synthetic secondary to be repurchased by Guardian.
Underwriters have a 30‑day option for up to an additional 900,000 shares. Guardian will not retain net proceeds from selling stockholders and expects the repurchases to complete by March 24, 2026.